Estramustine phosphate (Emcyt) as treatment for metastatic renal carcinoma.
Sixteen patients completed an adequate trial of estramustine phosphate for the management of metastatic renal cell carcinoma. Although no patient showed a complete or partial response, 9 (56 per cent) had stabilization of disease for a median of 44 weeks. Toxicity was not severe, but intolerance to the drug may limit its widespread use.
D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D004961:Estramustine / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009588:Nitrogen Mustard Compounds / Q000627:therapeutic use*; D012737:Sex Factors
D009588:Nitrogen Mustard Compounds; D004961:Estramustine